Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor.

Keravis, Thérèse

Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor. [electronic resource] - PloS one 2012 - e28899 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1932-6203

10.1371/journal.pone.0028899 doi


Adenine--analogs & derivatives
Animals
Cyclic AMP--metabolism
Cyclic Nucleotide Phosphodiesterases, Type 4--chemistry
Disease Progression
Female
Humans
Isoenzymes
Kidney--cytology
Lipopolysaccharides--pharmacology
Lupus Erythematosus, Systemic--drug therapy
Mice
Mice, Inbred CBA
Mice, Inbred MRL lpr
Pentoxifylline--therapeutic use
Phosphodiesterase 4 Inhibitors--therapeutic use
Proteinuria--drug therapy
Survival Rate
Tumor Necrosis Factor-alpha--metabolism
Xanthines--therapeutic use